Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study

Open access
Buda, Alessandro, Fossati, Roldano, Colombo, Nicoletta, Fei, Francesca, Floriani, Irene, Gueli Alletti, Desiderio, Katsaros, Dionyssios, Landoni, Fabio, Lissoni, Andrea, Malzoni, Carmine, Sartori, Enrico, Scollo, Paolo, Torri, Valter, Zola, Paolo, Mangioni, Costantino · 2005 · Journal of Clinical Oncology

Abstract

Purpose: Neoadjuvant chemotherapy may represent an alternative to irradiation in locally advanced squamous cell cervical cancer. Aims of this study were to compare a three-drug (paclitaxel, ifosfamide, and cisplatin [TIP]) with a two-drug (ifosfamide and cisplatin [IP]) regimen and to assess the prognostic value of pathologic response on survival. Patients and Methods: Patients (n = 219) were randomly assigned to ifosfamide 5 g/m 2 during 24 hours plus cisplatin 75 mg/m 2, or paclitaxel 175 mg/m 2 plus ifosfamide 5 g/m 2 during 24 hours and cisplatin 75 mg/m 2 every 3 weeks for three courses. Results: Grades 3 to 4 neutropenia, anemia, and thrombocytopenia were more frequent with TIP. We recorded four deaths related to toxicity. The optimal pathologic response (OPT) rate (residual disease < 3 mm stromal invasion) was higher with TIP than with IP (48% v 23%; odds ratio, 3.22; 95% CI, 1.69 to 5.88; P = .0003). At a median follow-up of 43.4 months, 79 women experienced disease progression or died (46 in the IP arm, 33 in the TIP arm). Patients receiving TIP experienced a treatment failure rate 25% less than those receiving IP, but this difference was not statistically significant (hazard ratio [HR], 0.75; 95% CI, 0.48 to 1.17; P = .20). Sixty-one patients died (37 in the IP arm, 24 in the TIP arm), and the HR of death was in favor of TIP, although not significantly (HR, 0.66; 95% CI, 0.39 to 1.10; P = .11). In patients assessable for response (n = 189), the average death rates were higher in the group that did not achieve OPT (HR, 5.88; 95% CI, 2.50 to 13.84; P < .0001). Conclusion: The TIP regimen is associated with a higher response rate than the IP regimen, without a statistically significant effect on overall survival. OPT was a prognostic factor for survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.04.172

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 194

Metadata

Authors
Buda, A., Fossati, R., Colombo, N., Fei, F., Floriani, I., Gueli Alletti, D., Katsaros, D., Landoni, F., Lissoni, A., Malzoni, C., Sartori, E., Scollo, P., Torri, V., Zola, P., & Mangioni, C.
Venue
Journal of Clinical Oncology
Published
2005-06-20
Volume
23
Issue
18
Pages
4137-4145
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2104522904
Cited by
194
References
1
FWCI
9.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. https://app.cochat.ai/papers/10.1200/jco.2005.04.172
The paper
Buda, A., Fossati, R., Colombo, N., Fei, F., Floriani, I., Gueli Alletti, D., Katsaros, D., Landoni, F., Lissoni, A., Malzoni, C., Sartori, E., Scollo, P., Torri, V., Zola, P., & Mangioni, C. (2005). Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.172

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.